ARIUS announces allowance of US patent for lead anti-cancer antibody

ARIUS Research Inc., has announced that the Company has received notice from the United States Patent and Trademark Office that a key patent for its lead anti-CD44 drug candidate will issue on August 7th, 2007, as US Patent Number 7,252,821.

This pivotal patent covers the ARH460-16-2 antibody itself, as well as the use of the antibody in the treatment of breast cancers. ARIUS now has 16 issued and allowed patents covering its antibody programs and discovery platform and over 150 patents pending.

The ARH460-16-2 antibody drug is in development by ARIUS for breast, prostate and liver cancers. The CD44 antigen that is targeted by this antibody has been identified as a cancer stem cell marker in several different malignancies. The discovery of cancer stem cells and the markers that distinguish this population of cancer cells from others represent a key advancement in the understanding of cancer. Such insights can be used to develop drugs, such as ARH460-16-2, to prevent the spread of cancer and extend survival in cancer patients. Recently ARIUS has also announced the initiation of a toxicology program in preparation for human clinical trials.

"ARIUS is having an extremely successful year," said Dr. David Young, President and CEO. "We have hit a number of critical technical milestones and the ongoing success of our patent strategy reflects the value we are building in the company. We are moving ahead to file our IND application and begin human clinical trials in 2008 with the U.S. FDA."

The Company also disclosed the departure of Dr. Robert Gundel, Chief Scientific Officer, from ARIUS.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MRI-guided SBRT reduces side effects in prostate cancer treatment